Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena - Proteomic and Metabolomic Approaches to Biomarker Discovery - page 347

targeted therapies emerge, and more antibodies
are commercialized. At the same time, there is
increasing demand to shift from large specimens
to small-core needle samples. Consequently, the
sample size will continue to shrink and the
complexity of the analyte repertoire will expand.
Thus, the future will bring greater demands on
the sensitivity, precision, and versatility of
RPMA technology. RPMA technology will
evolve

shift, and this may be the best predictor of resis-
tance or ef

cacy. The knowledge we gain from
the ongoing clinical research trials will shape
how signal pathway pro ling will be done in

the clinical practice of the future.

References
1. Agarwal R, Gonzalez-Angulo AM, Myhre S, et al.
Integrative analysis of cyclin protein levels identi

to utilize nanotechnology, third-

es

er and predictor of outcomes in
breast cancer. Clin Cancer Res 2009;15:3654 e 62.
2. Aguilar-Mahecha A, Cantin C, O

cyclin b1 as a classi

generation ampli cation chemistries, and new

antigen recognition technology so that the ulti-
mate clinical embodiment is a one-step tech-
nology from the user

Connor-McCourt M,
et al. Development of reverse phase protein micro-
arrays for the validation of clusterin, a mid-abundant
blood biomarker. Proteome Sci 2009;7:15.
3. Alhamdani MS, Schroder C, Hoheisel JD. Oncopro-
teomic pro

'

s perspective. We can
imagine a time in which readout is fully elec-
tronic or embodied in a bead array chip that
can be read on a DNA sequencer type instru-
ment. It may even be possible to achieve a multi-
plex assay with high sensitivity in a homogenous
(solution phase) format.
Genomic sequencing reveals dozens to
hundreds of mutations or chromosome aberra-
tions in an individual patient

'

ling with antibody microarrays. Genome
Med 2009;1:68.
4. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types
of diffuse large B-cell lymphoma identi ed by gene

ling. Nature 2000;403:503 e 11.
5. Anderson T, Wulfkuhle J, Liotta L, et al. Improved
reproducibility of reverse-phase protein microarrays
using array microenvironment normalization. Proteo-
mics 2009;9:5562 e 6.
6. Becker KF, Schott C, Hipp S, et al. Quantitative protein
analysis from formalin-

expression pro

s tumor. Presently,
there is no way to determine which of these
genetic changes are functionally important and
should be used as a basis for therapy. 10,11,63,80
The key utility of RPMA is to

'

xed tissues: implications for
translational clinical research and nanoscale molecular
diagnosis. J Pathol 2007;211:370 e 8.
7. Belluco C, Mammano E, Petricoin E, et al. Kinase
substrate protein microarray analysis of human colon
cancer and hepatic metastasis. Clin Chim Acta 2005;
357:180 e 3.
8. Bjorling E, Uhlen M. Antibodypedia, a portal for
sharing antibody and antigen validation data. Mol Cell
Proteomics 2008;7:2028 e 37.
9. Bobrow MN, Shaughnessy KJ, Litt GJ. Catalyzed
reporter deposition, a novel method of signal ampli-

fill this missing
functional gap. We believe that going forward
genomic clinical research protocols will increas-
ingly combine whole genome sequencing/tar-
geted resequencing with RNA Seq and RPMA
of tumor versus blood together with measure-
ment of circulating nucleic acids. RPMA
provides direct functional information about
which activated protein signal pathways have
hijacked the neoplastic cells, or the host microen-
vironment, and are the drivers of the disease.
Ongoing clinical trials employing RPMA may
reveal unexpected endpoints, pathway intercon-
nections, and activated pathways that correlate,
or do not correlate, with outcome or with
genomic or genetic data. We may

fication. II. Application to membrane immunoassays.
J Immunol Methods 1991;137:103 e 12.
10. Brennan DJ, O Brien SL, Fagan A, et al. Application of

DNA microarray technology in determining breast
cancer prognosis and therapeutic response. Expert
Opin Biol Ther 2005;5:1069 e 83.
11. Carlisle AJ, Prabhu VV, Elkahloun A, et al. Development
of a prostate cDNA microarray and statistical gene
expression analysis package. Mol Carcinog 2000;28:12 e 22.
12. Castagnoli L, Costantini A, Dall

'

find that acti-
vated proteins we expect to decrease following
therapy may do the opposite because of compen-
satory feedback or adaption to therapy or clonal

Armi C, et al. Selec-
tivity and promiscuity in the interaction network
mediated by protein recognition modules. FEBS Lett
2004;567:74 e 9.

'